Mga Batayang Estadistika
| LEI | 529900TQRID2UY164805 |
| CIK | 1280600 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acceleron Pharma Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36065 Acceleron Pharma Inc. (Exact name of registrant as specified in its c |
|
| November 24, 2021 |
XLRN / Acceleron Pharma Inc / Avoro Capital Advisors LLC - ACCELERON PHARMA INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acceleron Pharma Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00434H108 (CUSIP Number) Scott Epstein Avoro Capital Advisors LLC 110 Greene Street, Suite 800 New York, NY 10012 (212) 937-4970 Eleazer Klein, Esq. Adrian |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 ACCELERON PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other (Commission (I.R.S. Employer jurisdiction) |
|
| November 22, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 4 ACCELERON PHARMA INC. (Name of Subject Company (Issuer)) Astros Merger Sub, Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.00 |
|
| November 22, 2021 |
Press release issued by Merck & Co., Inc., dated November 22, 2021. Exhibit (a)(5)(L) FOR IMMEDIATE RELEASE Media Contacts: Jessica Fine Investor Contacts: Peter Dannenbaum (908) 608-4859 (908) 740-1037 Melissa Moody Steven Graziano (215) 407-3536 (908) 740-6582 Merck Completes Acquisition of Acceleron Pharma Inc. |
|
| November 22, 2021 |
Merck Completes Acquisition of Acceleron Pharma Inc. Exhibit (a)(5)(J) News Release FOR IMMEDIATE RELEASE Media Contacts: Jessica Fine (908) 608-4859 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Completes Acquisition of Acceleron Pharma Inc. |
|
| November 22, 2021 |
Amended and Restated Bylaws of the Company. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF Acceleron Pharma Inc. Article I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors (the |
|
| November 22, 2021 |
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc. Exhibit (a)(5)(I) News Release FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Completes Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company) ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00434H108 |
|
| November 22, 2021 |
Press release issued by Merck & Co., Inc., dated November 19, 2021. Exhibit (a)(5)(k) FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Completes Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 22, 2021 |
Amended and Restated Certificate of Incorporation of the Company. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACCELERON PHARMA INC. FIRST: The name of the corporation is Acceleron Pharma Inc. (hereinafter, the ?Corporation?). SECOND: The address of the Corporation?s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of its registered agent at |
|
| November 17, 2021 |
SC TO-T/A 1 d252291dsctota.htm SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 3 ACCELERON PHARMA INC. (Name of Subject Company (Issuer)) Astros Merger Sub, Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons |
|
| November 17, 2021 |
Exhibit (a)(5)(H) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company) ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00434H108 |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Acceleron Pharma Inc. (Name of Subject Company) Avoro Capital Advisors LLC Behzad Aghazadeh (Name of Persons Filing Statement) Common Stock, $0.001 per share (Title of Class of Securities) 00434H |
|
| November 17, 2021 |
Press release issued by Merck & Co., Inc., dated November 17, 2021. Exhibit (a)(5)(j) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company) ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00434H108 |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Acceleron Pharma Inc. (Name of Subject Company) Avoro Capital Advisors LLC Behzad Aghazadeh (Name of Persons Filing Statement) Common Stock, $0.001 per share (Title of Class of Securities) 00434H |
|
| November 10, 2021 | ||
| November 8, 2021 |
SC 14D9/A 1 tm2132291d1sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company) ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per sh |
|
| November 8, 2021 |
Press release issued by Merck & Co, Inc., dated November 8, 2021. Exhibit (a)(5)(I) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 8, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 ACCELERON PHARMA INC. (Name of Subject Company (Issuer)) Astros Merger Sub, Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.00 |
|
| November 8, 2021 |
Exhibit (a)(5)(G) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 4, 2021 |
Exhibit 99.1 Acceleron Reports Third Quarter 2021 Financial Results - Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL? (luspatercept-aamt) - - Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition scheduled for De |
|
| November 4, 2021 |
Exhibit 10.3 AMENDMENT TO THE EMPLOYMENT AGREEMENT This Amendment (?Amendment?), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (?Acceleron?), and Sujay Kango, EVP, Chief Commercial Officer (the ?Executive?), amends that certain Employment Agreement between Executive and Acceleron, dated as of February 12, 2018 (?Agreement?). Together Acceleron and |
|
| November 4, 2021 |
Exhibit 10.2 AMENDMENT TO THE EMPLOYMENT AGREEMENT This Amendment (?Amendment?), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (?Acceleron?), and Jay Backstrom, EVP, Research and Development (the ?Executive?), amends that certain Employment Agreement between Executive and Acceleron, dated as of December 10, 2019 (?Agreement?). Together Acceleron a |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 4, 2021 |
Exhibit 10.1 AMENDMENT TO THE EMPLOYMENT AGREEMENT This Amendment (?Amendment?), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (?Acceleron?), and Habib Dable, President and Chief Executive Officer (the ?Executive?), amends that certain Employment Agreement between Executive and Acceleron, dated as of September 23, 2016 (?Agreement?). Together Acce |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 4, 2021 |
Exhibit 10.5 AMENDMENT TO THE EMPLOYMENT AGREEMENT This Amendment (?Amendment?), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (?Acceleron?), and Adam Veness, SVP, General Counsel (the ?Executive?), amends that certain Amended and Restated Employment Agreement between Executive and Acceleron, dated as of June 5, 2019 (?Agreement?). Together Accele |
|
| November 4, 2021 |
Exhibit 10.4 AMENDMENT TO THE EMPLOYMENT AGREEMENT This Amendment (?Amendment?), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (?Acceleron?), and Kevin McLaughlin, SVP, Chief Financial Officer (the ?Executive?), amends that certain Employment Agreement between Executive and Acceleron, dated as of February 13, 2014, as amended (?Agreement?). Togeth |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company) ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00434H108 |
|
| November 1, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 ACCELERON PHARMA INC. (Name of Subject Company (Issuer)) Astros Merger Sub, Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.00 |
|
| November 1, 2021 |
Exhibit (a)(5)(F) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc. |
|
| November 1, 2021 |
Press release issued by Merck & Co, Inc., dated October 29, 2021. Exhibit 99.(a)(5)(H) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc. KENILWORTH, N.J., Oct. 29, 2021?Merck (NYSE: MRK), known as MSD outside the |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Acceleron Pharma Inc. (Name of Subject Company) Avoro Capital Advisors LLC Behzad Aghazadeh (Name of Persons Filing Statement) Common Stock, $0.001 per share (Title of Class of Securities) 00434H108 (CUSIP Number |
|
| October 27, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Acceleron Pharma Inc. (Name of Subject Company) Darwin Global Management Limited Abhishek Trehan (Name of Persons Filing Statement) Common Stock, $0.001 per share (Title of Class of Securities) 00434H108 (CUSIP Nu |
|
| October 13, 2021 |
SC 14D9 1 p21-2306sc14dn.htm ACCELERON PHARMA INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Acceleron Pharma Inc. (Name of Subject Company) Holocene Advisors, LP (Name of Persons Filing Statement) Common Stock, $0.001 per share (Title of Class of Securit |
|
| October 12, 2021 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ACCELERON PHARMA INC. |
|
| October 12, 2021 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| October 12, 2021 |
Exhibit (d)(2) August 17, 2021 Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, NJ 07033 Attention: Sunil A. Patel Senior Vice President and Head of Business & Licensing Development Ladies and Gentlemen: In connection with your interest in a possible negotiated business combination (the ?Possible Transaction?) with Acceleron Pharma Inc. a Delaware corporation (the ?Company?), you have reques |
|
| October 12, 2021 |
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc. Exhibit (a)(1)(F) News Release Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Merck Begins Tender Offer to Acquire Acceleron Pharma Inc. |
|
| October 12, 2021 |
Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of ACCELERON PHARMA INC. |
|
| October 12, 2021 |
? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ? ACCELERON PHARMA INC. (Name of Subject Company) ? ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) ? Common Stock, $0.001 par value per share (Title of Class of Securities) 00434H108 (CUS |
|
| October 12, 2021 |
Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of Acceleron Pharma Inc. |
|
| October 12, 2021 |
SC TO-T 1 d202184dsctot.htm SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company (Issuer)) Astros Merger Sub, Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common St |
|
| October 12, 2021 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ACCELERON PHARMA INC. |
|
| October 5, 2021 |
XLRN / Acceleron Pharma Inc / Avoro Capital Advisors LLC - ACCELERON PHARMA INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Acceleron Pharma Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00434H108 (CUSIP Number) Scott Epstein Avoro Capital Advisors LLC 110 Greene Street, Suite 800 New York, NY 10012 (212) 937-4970 Eleazer Klein, Esq. Adriana S |
|
| October 1, 2021 |
SC TO-C 1 d237989dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company — Issuer) ASTROS MERGER SUB, INC. a wholly owned subsidiary of MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Sto |
|
| October 1, 2021 |
EX-99.1 2 d237989dex991.htm EX-99.1 Exhibit 99.1 REFINITIV STREETEVENTS EDITED TRANSCRIPT XLRN.OQ - Acceleron Pharma Inc Acquired by Merck & Co Inc Call EVENT DATE/TIME: SEPTEMBER 30, 2021 / 12:00PM GMT OVERVIEW: On 09/30/21, XLRN and Merck announced they have entered into definitive agreement under which Merck, through a subsidiary, will acquire XLRN for $180 per share in cash for an approximate |
|
| September 30, 2021 |
EX-2.1 2 tm2128840d1ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among MERCK SHARP & DOHME CORP. ASTROS MERGER SUB, INC. and ACCELERON PHARMA INC. Dated as of September 29, 2021 TABLE OF CONTENTS Article I THE OFFER 2 Section 1.1. The Offer 4 Section 1.2. Company Consent; Schedule 14D-9 5 Section 1.3. Stockholder Lists 5 Article II THE MERGER 5 Section 2.1. The Merger 5 Section 2 |
|
| September 30, 2021 |
EX-99.2 2 tm2128840d2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 All Staff Email Good morning, Accelerators, At Acceleron, we have all committed to our mission to accelerate the discovery, development, and commercialization of innovative medicines to transform patients’ lives. Together, we have achieved remarkable milestones—from advancing an Acceleron-discovered molecule from the lab to successful comme |
|
| September 30, 2021 |
Letter to Vendors, Service Providers and Collaborators, dated September 30, 2021. EX-99.4 4 tm2128840d2ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Vendor/Service Provider/Collaborator Letter Today, we announced that we have entered into a definitive agreement to be acquired by Merck. I’ve attached a copy of the joint press release we issued for your reference. We believe this transaction is a testament to the unique company that we have built upon a strong foundation of innovation, pe |
|
| September 30, 2021 |
Investor presentation of Merck & Co., Inc., dated September 30, 2021. EX-99.4 5 d202184dex994.htm EX-99.4 Exhibit 99.4 Acquisition of Acceleron Pharma September 30, 2021Exhibit 99.4 Acquisition of Acceleron Pharma September 30, 2021 Confidential Agenda • Strategic Rationale | Rob Davis, Chief Executive Officer • Scientific Overview | Dr. Dean Li, President, Merck Research Labs (MRL) • Clinical Profile | Dr. Roy Baynes, SVP and Chief Medical Officer, MRL • Commercial |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 ACCELERON PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-36065 27-0072226 (state or other jurisdiction (Commission (I.R.S. Employer |
|
| September 30, 2021 |
SC14D9C 1 p21-2236sc14d9c.htm ACCELERON PHARMA INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Acceleron Pharma Inc. (Name of Subject Company) Avoro Capital Advisors LLC Behzad Aghazadeh (Name of Persons Filing Statement) Common Stock, $0.001 per share (Ti |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company ? Issuer) ASTROS MERGER SUB, INC. a wholly owned subsidiary of MERCK SHARP & DOHME CORP. (Names of Filing Persons ? Offerors) Common Stock, par value $0.001 per share (Titl |
|
| September 30, 2021 |
EX-99.2 Exhibit 99.2 An important moment for patients, our pipeline, and our purpose Dear Colleagues, Today marks an important moment for patients, our pipeline, and our purpose. I am very pleased to announce our acquisition of Acceleron Pharma, a publicly traded biopharmaceutical company, focused on harnessing the power of the TGF-beta protein superfamily, known to play a central role in the regu |
|
| September 30, 2021 |
Social media posts of Merck & Co., Inc. or its representatives, dated September 30, 2021. EX-99.3 4 d202184dex993.htm EX-99.3 Exhibit 99.3 Merck Twitter post: Today we announced that we have entered into a definitive agreement to acquire @AcceleronPharma to complement and strengthen our #cardiovascular pipeline. Learn more: http://merck.us/39Td5p6 $MRK Merck LinkedIn post: Today we announced that we have entered into a definitive agreement to acquire Acceleron Pharma to complement and |
|
| September 30, 2021 |
Employee Q&A, dated September 30, 2021. Exhibit 99.3 Employee Q&A 1. Why did we agree to sell Acceleron? a. We have an exceptional team that has created a valuable company with a commercial-stage asset in rare anemias and mid- to late-stage pipeline focused on patients with rare pulmonary diseases. On balance, when taking into account the best interests of our shareholders and the patients we currently serve and hope to serve in the fut |
|
| September 30, 2021 |
Exhibit 99.1 Confidential News Release FOR IMMEDIATE RELEASE Merck Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Merck Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Acceleron Media Contact: Matt Fearer (617) 301-9557 Acceleron Investor Contacts: Todd James (617) 649-9393 Jamie Bernard, IRC (617) 301-9650 Merck to Acquire Acceleron Phar |
|
| September 30, 2021 |
Email to Key Opinion Leaders, dated September 30, 2021. Exhibit 99.5 Today, Acceleron and Merck (MSD outside of USA and Canada) announced that the companies have entered into a definitive agreement under which Merck will acquire Acceleron. Please see the news release here. On behalf of the entire team at Acceleron, I want to thank you for your support of the sotatercept clinical program. Your role remains essential for successfully advancing the clinic |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ACCELERON PHARMA INC. (Name of Subject Company) ACCELERON PHARMA INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 00434H108 (CUSIP Number of C |
|
| September 30, 2021 |
Joint press release issued by Merck & Co., Inc. and Acceleron Pharma Inc., dated September 30, 2021. Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215) 407-3536 Merck Investor Contacts: Peter Dannenbaum (908) 740-1037 Steven Graziano (908) 740-6582 Acceleron Media Contact: Matt Fearer (617) 301-9557 Acceleron Investor Contacts: Todd James (617) 649-9393 Jamie Bernard, IRC (617) 301-9650 Merck to Acquire Acceleron Pharma Inc. Acqui |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| August 5, 2021 |
Exhibit 99.1 Acceleron Reports Second Quarter 2021 Financial Results - Highlighted ongoing and planned trials in rare pulmonary diseases and presented vision and strategy for long-term growth at June R&D Day - - Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Thoracic Society (ATS) 2021 International |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 5, 2021 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[* * *]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATION August 2, 2011 CERT |
|
| July 28, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 22, 2021 |
R E S E A R C H & D E V E L O P M E N T D A Y 2 0 2 1 J U N E 2 2 , 2 0 2 1 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY?S STRATEGY, FUTURE PLANS AND PROSPECTS ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE INCLUDED IN THE FORWARD-LOOKING STATEMENTS DUE TO VARIOUS THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESENTATION ARE BA |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 17, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 17, 2021 |
EX-99.1 2 xlrn-20210611xform8kxex991.htm EX-99.1 Exhibit 99.1 Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally well tolerated |
|
| May 19, 2021 |
EX-99.2 3 xlrn-20210519ex992.htm EX-99.2 Exhibit 99.2 Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference – Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotaterce |
|
| May 19, 2021 |
EX-99.1 2 xlrn-20210519ex991.htm EX-99.1 Exhibit 99.1 Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference - Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotate |
|
| May 19, 2021 |
A T S 2 0 21 I N T E R N A T I O N A L C O N F E R E N C E A C C E L E R O N I N V E S T O R A N D A N A L Y S T C A L L M A Y 1 9 , 2 0 2 1 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY?S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the development and commercialization of sotatercept in pulmonary arterial hypertension (?PAH?) and of the Company?s other compounds, the timeline for clinical development and regulatory approval of the Company?s compounds and the expected timing for reporting of data from ongoing clinical trials. |
|
| May 19, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2021 |
EX-99.1 2 xlrn-20210506ex991.htm EX-99.1 Exhibit 99.1 Acceleron Reports First Quarter 2021 Financial Results - PULSAR Phase 2 trial results published in New England Journal of Medicine - - Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society (ATS) 2021 International Conference on Ma |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| April 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 22, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 5, 2021 |
Exhibit 99.1 Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference ? Conference to include interim results from the open-label extension of the PULSAR Phase 2 trial showing consistent or improved responses in efficacy endpoints among sotatercept-treated patie |
|
| April 5, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| February 25, 2021 |
EX-10.19 6 xlrn-20201231xex1019.htm EXHIBIT-10.19 Exhibit 10.19 Name: [•] Number of Shares of Stock subject to Stock Option: [•] Exercise Price Per Share: $[•] Date of Grant: [•] Vesting Start Date: [•] Acceleron Pharma Inc. 2013 Equity Incentive Plan NON-STATUTORY STOCK OPTION AGREEMENT This agreement (this “Agreement”) evidences a stock option granted by Acceleron Pharma Inc. (the “Company”) to |
|
| February 25, 2021 |
EX-99.1 2 xlrn-20210225xform8kxex991.htm EXHIBIT-99.1 Exhibit 99.1 Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results - Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions - - STELLAR Phase 3 trial initiated with sotatercept |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Exhibit 21.1 List of Subsidiaries of Acceleron Pharma Inc. Name State or other Jurisdiction of Incorporation or Organization Acceleron Securities Corp. Massachusetts Acceleron Holding Ltd. Bermuda Acceleron Pharma Switzerland AG Switzerland |
|
| February 25, 2021 |
Form of Performance-Based Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan Exhibit 10.22 Name: [?] Target Number of PSUs subject to Award: [?] Date of Grant: [?] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This agreement (including any exhibits hereto, this ?Agreement?) evidences an award (this ?Award?) of performance-based restricted stock units (the ?PSUs?) granted by Acceleron Pharma Inc. (the ?Company?) to |
|
| February 25, 2021 |
Exhibit 10.12 December 10, 2019 Jay T. Backstrom, M.D., M.P.H. Dear Jay: This letter agreement (“Agreement”) sets forth the terms and conditions of your employment with Acceleron Pharma Inc. (the “Company”). 1.Position and Duties. You shall serve, on a full-time basis, as the Company’s Executive Vice President, Research and Development, reporting to the Company’s Chief Executive Officer. You agree |
|
| February 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36 |
|
| February 25, 2021 |
EX-10.21 8 xlrn-20201231xex1021.htm EXHIBIT-10.21 Exhibit 10.21 Name: [•] Number of Restricted Stock Units subject to Award: [•] Date of Grant: [•] Vesting Date: [•] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This agreement (the “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Acceleron Pha |
|
| February 25, 2021 |
EX-10.10 2 xlrn-20201231xex1010.htm EXHIBIT-10.10 Exhibit 10.10 June 5, 2019 Adam M. Veness, Esq. Dear Adam: This letter agreement (“Agreement”) sets forth the terms and conditions of your employment with Acceleron Pharma Inc. (the “Company”), as amended and restated as of the date set forth above. 1.Position and Duties. You shall serve, on a full-time basis, as the Company’s Vice President, Gener |
|
| February 25, 2021 |
EX-10.18 5 xlrn-20201231xex1018.htm EXHIBIT-10.18 Exhibit 10.18 Name: [•] Number of Shares of Stock subject to Stock Option: [•] Exercise Price Per Share: $[•] Date of Grant: [•] Vesting Start Date: [•] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT This agreement (this “Agreement”) evidences a stock option granted by Acceleron Pharma Inc. (the “Company”) to |
|
| February 25, 2021 |
EX-10.20 7 xlrn-20201231xex1020.htm EXHIBIT-10.20 Exhibit 10.20 Name: [•] Number of Restricted Stock Units subject to Award: [•] Date of Grant: [•] Vesting Date: [•] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This agreement (the “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Acceleron Pha |
|
| February 25, 2021 |
EX-10.11 3 xlrn-20201231xex1011.htm EXHIBIT-10.11 Exhibit 10.11 December 2, 2019 Jay T. Backstrom, M.D. Dear Jay: I am pleased to offer you the position of Executive Vice President, Research and Development with Acceleron Pharma Inc. (the “Company”) reporting to Habib Dable. Your start date for employment is currently set at December 19, 2019 and may occur earlier upon mutual consent. Base Pay You |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Acceleron Pharma Inc. Title of Class of Securities: Common Stock CUSIP Number: 00434H108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 4, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| January 11, 2021 |
EX-99.1 2 xlrn-20210111ex991.htm EX-99.1 J . P . M O R G A N 3 9 T H A N N U A L H E A L T H C A R E C O N F E R E N C E J A N U A R Y 1 1 , 2 0 2 0 Exhibit 99.1 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the development and commercialization of the Company's com |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2020 |
xlrn-20201113ex993 Exhibit 99.3 AHA 2020 Virtual: Updates from the PULSAR and SPECTRA Trials of Sotatercept in PAH November 13, 2020 Sotatercept is an investigational therapy that is not approved for any use in any country. Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regard |
|
| November 13, 2020 |
Exhibit 99.1 Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions – Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data f |
|
| November 13, 2020 |
Exhibit 99.2 Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions – Treatment with sotatercept in first set of patients in the ongoing SPECTRA Phase 2 trial was associated with substantial improvements in hemodynamics, exercise tolerance and exercise capacity at |
|
| November 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 5, 2020 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| November 5, 2020 |
Exhibit 99.1 Acceleron Reports Third Quarter 2020 Operating and Financial Results - Acceleron recognized approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL® (luspatercept-aamt) - - REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment of transfusion-dependent anemia in adults with bet |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| October 2, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission F |
|
| October 2, 2020 |
xlrn-20201002ex991 Exhibit 99.1 Phase 3 Trial Design Webinar October 2, 2020 Sotatercept is an investigational therapy that is not approved for any use in any country. Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the development and commercialization of sotatercept |
|
| September 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commissio |
|
| August 6, 2020 |
Exhibit 99.1 Acceleron Reports Second Quarter 2020 Operating and Financial Results - Acceleron recognized approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) and a $25.0 million regulatory-based milestone from Bristol Myers Squibb - - REBLOZYL, the first and only erythroid maturation agent, was approved by t |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 6, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| July 16, 2020 |
XLRN / Acceleron Pharma Inc. / BRISTOL MYERS SQUIBB CO - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Acceleron Pharma Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00434H108 (CUSIP Number) Sandra Leung, Esq. Bristol-Myers Squibb Company 430 East 29th Street, 14th Floor New York, New York 10016 (212) 546-3309 (Name, |
|
| July 16, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with the other Reporting Person (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including any and all amendments thereto) with respect to Com |
|
| July 2, 2020 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS EX-99.1 4 tm2023622d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following table sets forth the various expenses, other than any underwriting discounts and commissions, in connection with the sale and distribution of the securities being registered. Securities and Exchange Commission Registration Fee $ |
|
| July 2, 2020 |
Underwriting Agreement, dated June 30, 2020, by and among the Company and the Representatives EX-1.1 2 tm2023622d3ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version Acceleron Pharma Inc. 4,864,864 Shares1 Common Stock ($0.001 par value) Underwriting Agreement New York, New York June 30, 2020 J.P. Morgan Securities LLC SVB Leerink LLC Cowen and Company, LLC As Representatives of the several Underwriters, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Lee |
|
| July 2, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction (Commission (I.R.S. Employer of i |
|
| July 2, 2020 |
424B2 1 a2242008z424b2.htm 424B2 Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) File No. 333-220522 CALCULATION OF REGISTRATION FEE(1) Title of Each Class of Securities to be Registered Amount to Be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, $0.001 par valu |
|
| June 30, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 24, 2020 |
Press release of Acceleron Pharma Inc. dated June 24, 2020 Exhibit 99.1 Acceleron Presents Topline Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension - Data presented during ‘Breaking News’ Session of the American Thoracic Society 2020 Virtual Conference (ATS 2020 Virtual) show the PULSAR trial achieved its primary endpoint: a statistically significant mean reduction in pulmonary vascular resistance (PVR) - |
|
| June 24, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 24, 2020 |
Slide presentation of Acceleron Pharma Inc. dated June 24, 2020 xlrn20200624exhibit992 Exhibit 99.2 ATS 2020 Virtual: PULSAR Phase 2 Trial Results of Sotatercept in PAH June 24, 2020 1 Sotatercept is an investigational therapy that is not approved for any use in any country. Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the deve |
|
| June 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2020 |
Exhibit 99.1 Acceleron Reports First Quarter 2020 Operating and Financial Results - REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS) - - REBLOZYL received positive CHMP opinion for the treatment of adults with transfusion-dependent anemia in lower-risk MDS and beta-thal |
|
| May 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2020 |
Exhibit 10.1 VIA EMAIL March 10, 2020 Celgene Corporation 86 Morris Avenue Summit, NJ 07901 Re: Clarification of Rights and Obligations under the Sotatercept Agreement (as defined below) Dear Sir or Madam: Reference is hereby made to that certain Amended and Restated Collaboration, License and Option Agreement by and between Acceleron Pharma Inc. (“Acceleron”) and Celgene Corporation (“Celgene”), |
|
| May 5, 2020 |
Exhibit 99.2 Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertension First therapeutic to receive PRIME designation in pulmonary arterial hypertension since the EMA established the program in 2016 PRIME designation comes just three weeks after US FDA granted sotatercept Breakthrough Therapy designation Cambri |
|
| May 5, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 5, 2020 |
Exhibit 99.1 Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes Recommendation for approval based on results from pivotal Phase 3 MEDALIST and BELIEVE studies PRINCETON, NJ and CAMBRIDGE, MA (April 30, 2020) – Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that |
|
| April 16, 2020 |
XLRN / Acceleron Pharma Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 16, 2020 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 16, 2020; Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 9, 2020 |
Exhibit 99.1 Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2013 Cambridge, Mass. – April 8, 2020 – Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, |
|
| April 9, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 9, 2020 |
Exhibit 99.1 Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 – Cambridge, Mass. – March 9, 2020 – Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated |
|
| March 9, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 27, 2020 |
Exhibit 4.4 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Acceleron Pharma Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only. This summary is qualified in its entirety by reference to our restated certificate of incorporation and amended and restated by-laws, both of which have been filed with the Securities and Exchange Commission and are inc |
|
| February 27, 2020 |
Exhibit 99.1 Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results - REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication |
|
| February 27, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36 |
|
| February 27, 2020 |
Form of Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan Exhibit 10.21 Name: [●] Number of Restricted Stock Units subject to Award: [●] Date of Grant: [●] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This agreement (the “Agreement”) evidences an award (the “Award”) of restricted stock units (the “Restricted Stock Units”) granted by Acceleron Pharma Inc. (the “Company”) to the undersigned (the “Participant”) purs |
|
| February 27, 2020 |
Form of Non-Statutory Stock Option Agreement under the 2013 Equity Incentive Plan Exhibit 10.19 Name: [●] Number of Shares of Stock subject to Stock Option: [●] Exercise Price Per Share: $[●] Date of Grant: [●] Vesting Start Date: [●] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT This agreement (this “Agreement”) evidences a stock option granted by Acceleron Pharma Inc. (the “Company”) to the undersigned (the “Optionee”) pursuant to and s |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2020 |
Exhibit 21.1 List of Subsidiaries of Acceleron Pharma Inc. Name State or other Jurisdiction of Incorporation or Organization Acceleron Securities Corp. Massachusetts Acceleron Holding Ltd. Bermuda |
|
| February 27, 2020 |
As filed with the Securities and Exchange Commission on February 27, 2020 As filed with the Securities and Exchange Commission on February 27, 2020 Registration No. |
|
| February 27, 2020 |
Form of Performance-Based Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan Exhibit 10.22 Name: [●] Target Number of PSUs subject to Award: [●] Date of Grant: [●] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This agreement (including any exhibits hereto, this “Agreement”) evidences an award (this “Award”) of performance-based restricted stock units (the “PSUs”) granted by Acceleron Pharma Inc. (the “Company”) to |
|
| February 12, 2020 |
XLRN / Acceleron Pharma Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01678-acceleronpharmainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Acceleron Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 00434H108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to desi |
|
| January 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| January 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2020 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2019 |
Exhibit 99.1 REBLOZYL (LUSPATERCEPT-AAMT) STUDIES EVALUATING TREATMENT OF ANEMIA IN RARE BLOOD DISEASES PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called INDEPENDENCE |
|
| December 13, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| December 9, 2019 |
Exhibit 99.1 Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes PRINCETON, N.J. & CAMBRIDGE, Mass. – Dec. 3, 2019 – Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory |
|
| December 9, 2019 |
Exhibit 99.2 Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt) PRINCETON, N.J. & CAMBRIDGE, Mass. — Dec. 6, 2019 — Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug Administr |
|
| December 9, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| December 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 8, 2019 |
Exhibit 99.1 FDA APPROVES REBLOZYL® (LUSPATERCEPT-AAMT) FOR THE TREATMENT OF ANEMIA IN ADULTS WITH BETA THALASSEMIA WHO REQUIRE REGULAR RED BLOOD CELL TRANSFUSIONS REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA-approved treatment for anemia in beta thalassemia November 8, 2019 – |
|
| November 8, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 6, 2019 |
EX-99.1 2 xlrn-20191106ex991.htm EXHIBIT 99.1 Exhibit 99.1 Acceleron Reports Third Quarter 2019 Operating and Financial Results - FDA’s review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing - - Six clinical abstracts accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting- Cambridge, Mass. – November 6, 2019 – Acceleron |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commission |
|
| November 6, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| September 16, 2019 |
Exhibit 99.1 Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline results from the Phase 2 trial of ACE-083 in C |
|
| September 16, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 001-36065 27-0072226 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 xlrn-20190806form8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) |
|
| August 5, 2019 |
Exhibit 99.1 Acceleron Reports Second Quarter 2019 Operating and Financial Results - BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Agency, respectively - - Acceleron receives $25 million milestone payment from Celgene for luspatercept’s BLA acceptance and MAA validation |
|
| August 5, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| June 10, 2019 |
8-K 1 xlrn-2019x06x10form8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) |
|
| June 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27 |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27- |
|
| May 9, 2019 |
Exhibit 99.1 Acceleron Reports First Quarter 2019 Operating and Financial Results – Luspatercept Biologics License Application (BLA) and Marketing Authorization Application (MAA) submitted in April 2019 – – Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) expected in the second half of 2019 and Charcot-Marie-Tooth disease (CMT) anticipated in Q1 2020 |
|
| May 9, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| April 12, 2019 |
XLRN / Acceleron Pharma Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 12, 2019 |
XLRN / Acceleron Pharma Inc. DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 2 |
|
| April 5, 2019 |
Acceleron Discontinues Development of Phase 1 Molecule ACE-2494 Exhibit 99.1 Acceleron Discontinues Development of Phase 1 Molecule ACE-2494 Cambridge, Mass. – April 4, 2019 – Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic muscle agent the company had been stu |
|
| April 5, 2019 |
Exhibit 99.2 CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE SUBMISSION OF LUSPATERCEPT BIOLOGICS LICENSE APPLICATION TO U.S. FDA BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications EMA marketing application for both indications planned for Q2:19 Summit, N.J. & Cambridge, Mass. — (April 5, 2019) — Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (N |
|
| February 27, 2019 |
XLRN / Acceleron Pharma Inc. S-8 S-8 1 xlrnforms-82019.htm S-8 As filed with the Securities and Exchange Commission on February 27, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 ACCELERON PHARMA INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or or |
|
| February 27, 2019 |
Exhibit 99.1 Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results - MEDALIST and BELIEVE Phase 3 trial presentations at the 60th American Society of Hematology (ASH) Annual Meeting both selected for “Best of ASH” - - Luspatercept Biologics License Application (BLA) submission expected in April 2019 - - Part 2 results from the ACE-083 Phase 2 trials in facioscapulohum |
|
| February 27, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Numbe |
|
| February 27, 2019 |
Employment Agreement between Robert K. Zeldin and Acceleron Pharma Inc., dated as of June 29, 2018 10-K 1 xlrn-20181231x10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from |
|
| February 27, 2019 |
Employment Agreement between Sujay Kango and Acceleron Pharma Inc., dated as of February 12, 2018 EX-10.12 3 xlrn-20181231xex1012.htm EXHIBIT 10.12 Exhibit 10.12 February 12, 2018 Mr. Sujay Kango Dear Sujay: This letter agreement (“Agreement”) sets forth the terms and conditions of your employment with Acceleron Pharma Inc. (the “Company”). 1.Position and Duties. You shall serve, on a full-time basis, as the Company’s Senior Vice President and Chief Commercial Officer, reporting to the Company |
|
| February 27, 2019 |
Offer Letter between Robert K. Zeldin and Acceleron Pharma Inc., dated as of June 15, 2018 Exhibit 10.13 June 15, 2018 Robert K. Zeldin, MD Dear Robert: It is my pleasure to extend to you our offer of employment for the position of Executive Vice President and Chief Medical Officer with Acceleron Pharma Inc. (the “Company”). In this role, you will report to me, President and Chief Executive Officer, and we have agreed that your start will be June 29, 2018. The details of your compensati |
|
| February 27, 2019 |
Employment Agreement between Robert K. Zeldin and Acceleron Pharma Inc., dated as of June 29, 2018 EX-10.14 5 xlrn-20181231xex1014.htm EXHIBIT 10.14 Exhibit 10.14 June 29, 2018 Robert K. Zeldin, MD Dear Robert: This letter agreement (“Agreement”) sets forth the terms and conditions of your employment with Acceleron Pharma Inc. (the “Company”). 1.Position and Duties. You shall serve, on a full-time basis, as the Company’s Executive Vice President and Chief Medical Officer, reporting to the Compa |
|
| February 27, 2019 |
Offer Letter between Sujay Kango and Acceleron Pharma Inc., dated as of December 29, 2017 EX-10.11 2 xlrn-20181231xex1011.htm EXHIBIT 10.11 Exhibit 10.11 December 29, 2017 Via Overnight Mail Sujay Kango Dear Sujay: I am pleased to offer you the position of Senior Vice President and Chief Commercial Officer with Acceleron Pharma Inc. (the “Company”) reporting to Habib Dable. This offer will expire at the close of business five days after the date of this offer letter. If you accept our |
|
| February 11, 2019 |
XLRN / Acceleron Pharma Inc. / VANGUARD GROUP INC Passive Investment acceleronpharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Acceleron Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 00434H108 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate |
|
| January 22, 2019 |
SC 13D/A 1 tv511274sc13da.htm AMENDMENT NO. 6 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Acceleron Pharma Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00434H108 (CUSIP Number) Mark J. Alles Chief Executive Officer Celgene Corporation 86 Morri |
|
| January 17, 2019 |
Underwriting Agreement, dated January 15, 2019, by and among the Company and the Representatives Exhibit 1.1 Acceleron Pharma Inc. 5,348,838 Shares(1) Common Stock ($0.001 par value) Underwriting Agreement New York, New York January 15, 2019 Citigroup Global Markets Inc. J.P. Morgan Securities LLC SVB Leerink LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o J.P. Morgan Securities LLC 383 Madison Avenue New |
|
| January 17, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 a19-306118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-360 |
|
| January 17, 2019 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following table sets forth the various expenses, other than any underwriting discounts and commissions, in connection with the sale and distribution of the securities being registered. Securities and Exchange Commission Registration Fee $ 32,058 Printing and engraving expenses 25,00 |
|
| January 17, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Filed Pursuant to Rule 424(b)(2) File No. |
|
| January 14, 2019 |
Subject to completion, dated January 14, 2019 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 7, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) |
|
| January 7, 2019 |
xlrn20190107form8kex991 Exhibit 99.1 Corporate Presentation January 7, 2019 1 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company’s compounds and the e |
|
| December 3, 2018 |
xlrn20181203ex991 Exhibit 99.1 The BELIEVE Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions Maria Domenica Cappellini, Vip Viprakasit, Ali Taher, Pencho Georgiev, Kevin H.M. Kuo, Thomas Coates, Ersi Voskaridou, Hong Keng Liew, Idit Pazgal-Kobrowski, Gianluca Forni |
|
| December 3, 2018 |
xlrn20181203ex993 Exhibit 99.3 ASH 2018 MEDALIST & BELIEVE Phase 3 Trial Presentation Highlights December 3, 2018 ASH 2018 Call Agenda Introduction Welcome/Agenda – Todd James, IRC Luspatercept and ASH 2018 Overview – Habib Dable MEDALIST Phase 3 Trial Results Phase 3 Results Alan F. List, M.D. – Moffitt Cancer Center BELIEVE Phase 3 Trial Results Maria Domenica Cappellini, M.D. – University of Mi |
|
| December 3, 2018 |
xlrn20181203ex992 Exhibit 99.2 The MEDALIST Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) Associated Anemia With Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, R |
|
| December 3, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number |
|
| October 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number |
|
| October 30, 2018 |
Exhibit 99.1 Acceleron Reports Third Quarter 2018 Operating and Financial Results – MEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes (MDS) and beta-thalassemia, respectively, are expected to be presented at the 60th American Society of Hematology (ASH) Annual Meeting – – COMMANDS Phase 3 trial in patients with lower-risk MDS who are treatment naïve has been initiated – – Par |
|
| October 30, 2018 |
XLRN / Acceleron Pharma Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| August 2, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) |
|
| August 2, 2018 |
Exhibit 99.1 Acceleron Reports Second Quarter 2018 Operating and Financial Results – MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints – – ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway – – PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension – Cambridge, Mass. – |
|
| August 2, 2018 |
Exhibit 10.1 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATION August 2, 2011 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDEN |
|
| August 2, 2018 |
XLRN / Acceleron Pharma Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| July 26, 2018 |
Exhibit Exhibit 99.1 |
|
| July 26, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 2 |
|
| July 9, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27 |
|
| July 9, 2018 |
Exhibit 99.1 CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III ‘BELIEVE’ STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA Results showed a significant reduction in transfusion burden compared to placebo Safety profile generally consistent with previously reported data Regulatory submissions planned in the United States and Europe i |
|
| June 28, 2018 |
Exhibit 99.1 CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS IN PHASE III ‘MEDALIST’ STUDY IN PATIENTS WITH LOW-TO-INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES Results showed significant improvement in red blood cell transfusion independence compared to placebo Safety profile generally consistent with previously published data Regulatory submissions planned |
|
| June 28, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 2 |
|
| June 20, 2018 |
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association - Clinically meaningful increases in hemoglobin and reductions in red blood cell transfusion burden observed through 36 months – - Top-line results from the BELIEVE Phase 3 trial are on track for the middle of 2018 - CAMBRIDGE, MA – June 15, 2018 – Acceleron Pharma Inc. |
|
| June 20, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 2 |
|
| June 7, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27 |
|
| June 5, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27 |
|
| June 5, 2018 |
Exhibit 99.1 Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting – Multiple patients continue on treatment with clinically meaningful increases in hemoglobin and reduction in red blood cell transfusions surpassing 3 years – – Top-line results from the MEDALIST Phase 3 trial are on track for the middle of 2018 |
|
| May 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27 |
|
| May 8, 2018 |
Exhibit 99.1 Acceleron Reports First Quarter 2018 Operating and Financial Results – Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept expected in mid-2018 – – ACE-083 advances into Part 2 of the ongoing Phase 2 trial in facioscapulohumeral muscular dystrophy – – PULSAR Phase 2 trial with sotatercept in pulmonary arterial hypertension on track to initiate in Q2 2018 – Ca |
|
| May 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) 27- |
|
| May 8, 2018 |
XLRN / Acceleron Pharma Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| April 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission File Number) |
|
| April 13, 2018 |
XLRN / Acceleron Pharma Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 13, 2018 |
XLRN / Acceleron Pharma Inc. DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 27, 2018 |
XLRN / Acceleron Pharma Inc. S-8 Document As filed with the Securities and Exchange Commission on February 27, 2018 Registration No. |
|
| February 27, 2018 |
Exhibit Exhibit 99.1 Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results - Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept are expected in mid-2018 - - Plans to advance neuromuscular agent ACE-083 into Part 2 of the ongoing Phase 2 trials in facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease - - Expanded pipeline with sotater |
|
| February 27, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission F |
|
| February 27, 2018 |
Amended and Restated By-laws, as amended Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ACCELERON PHARMA INC. SECTION 1 -STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of Acceleron Pharma Inc., a Delaware corporation (the “Corporation”) for the election of directors to succeed those whose term expire and for the transaction of such other business as may properly come before the meeting shall be held at the pl |
|
| February 27, 2018 |
XLRN / Acceleron Pharma Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-36 |
|
| February 8, 2018 |
XLRN / Acceleron Pharma Inc. / VANGUARD GROUP INC Passive Investment acceleronpharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Acceleron Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 00434H108 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate |
|
| January 8, 2018 |
Exhibit Exhibit 99.2 Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy - Mean total muscle volume increases of over 12% in the tibialis anterior and biceps brachii muscle cohorts - - Company plans to initiate Part 2 of the FSHD Phase 2 trial in Q2 2018 - Cambridge, Mass. ? January 8, 2018 ? Acceleron Pharma Inc. (NASDAQ: |
|
| January 8, 2018 |
xlrn20180108form8kex991 JP Morgan Healthcare Conference January 2018 Exhibit 99.1 Acceleron Forward-Looking Statements 2 THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY?S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company?s compounds and |
|
| January 8, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission Fil |
|
| January 3, 2018 |
8-K 1 xlrn-20180103form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2018 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) |
|
| January 3, 2018 |
Exhibit Exhibit 10.1 SEPARATION AND TRANSITION AGREEMENT Matthew L. Sherman, M.D. Dear Matt: The purpose of this letter agreement (this ? Agreement ?) is to confirm the terms of the remainder of your employment with Acceleron Pharma Inc. (the ? Company ?) and your separation from the Company. Reference is made to the letter agreement between you and the Company dated August 26, 2013, as amended by |
|
| December 18, 2017 |
Financial Statements and Exhibits, Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2017 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission F |
|
| December 18, 2017 |
Exhibit Exhibit 99.1 Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59 th Annual Meeting of the American Society of Hematology - Preliminary results show treatment with luspatercept increases hemoglobin and achieves durable red blood cell transfusion independence in patients with lower-risk myelodysplastic syndromes - - Conferenc |
|
| November 15, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2017 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission F |
|
| November 7, 2017 |
Exhibit Exhibit 99.1 Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results - Presented vision and strategic focus in hematological, neuromuscular, and pulmonary diseases at September R&D Day - - Obtained the rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension; robust preclinical results show potential for first-in-cla |
|
| November 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36065 (Commission Fi |
|
| November 7, 2017 |
Exhibit 10.2 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATION THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CO |
|
| November 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| September 25, 2017 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. The following table sets forth the various expenses, other than any underwriting discounts and commissions, in connection with the sale and distribution of the securities being registered. Securities and Exchange Commission Registration Fee $ 26,657 Printing and engraving expenses 25,0 |
|
| September 25, 2017 |
Underwriting Agreement, dated January 5, 2016, by and among the Company and the Representatives EX-1.1 2 a17-222455ex1d1.htm EX-1.1 Exhibit 1.1 Acceleron Pharma Inc. 5,405,406 Shares(1) Common Stock ($0.001 par value) Underwriting Agreement New York, New York September 20, 2017 J.P. Morgan Securities LLC Citigroup Global Markets Inc. Leerink Partners LLC As Representatives of the several Underwriters, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Citigroup Gl |
